PEP Talk 2007 January 8-12, 2007

PEP Talk 2007 January 8-12, 2007
San Diego, CA
Success builds success!
Partnering brings progress, options, efficiency, shared resources, knowledge, and profitability. Partnerships pay great dividends which is why many leading edge companies now recognize the value of a partnership approach. Cambridge Healthtech Institute's 2nd Annual PepTalk Partnering Forum focuses on early-stage companies developing promising therapeutic, diagnostic, prognostic products, or tools to support the proteomic revolution. This unique format is designed to meet the needs of both emerging companies and senior managers responsible for partnering and collaborating with pharmaceutical, biotechnical, and drug development technology companies.
Companies or researchers interested in being considered for a showcase presentation are asked to submit a brief summary of what the company or technology has to offer, how it differs from the competitors, and what type of partnering deals are of interest.
January 9-10, 2007
Great strides have been made in the expression of proteins for structure and characterization studies, as well as for therapeutics and diagnostics. However, with these strides have come new obstacles. Higher throughput expression and purification, as well as more flexible expression systems and techniques are in even greater demand now to support the needs of the research pipeline. It has become even more important to prevent problems in protein expression by wise choices in data analysis well before the task goes into the laboratory. This conference will explore the newest data and technologies relating to the expression and characterization of proteins for biological understanding and therapeutics, as well as strategies to make the eventual expression of these proteins more effective, efficient and trouble-free.
January 9-10, 2007
Plasma, the most sampled proteome, is both the most useful and the most difficult to characterize. While human plasma represents an attractive source for disease biomarker discovery, the extreme complexity and large dynamic range in protein concentrations present significant challenges for characterization, candidate biomarker discovery, and validation. The measurement and characterization of plasma proteins in their relationship to health and disease is attainable as basic researchers, diagnosticians, clinicians, and drug developers utilize and develop standards, protocols, and clinically significant cost effective assays. As a core component of CHI?s 6th Annual PepTalk event, Prospecting the Plasma Proteome addresses the vast potential, current progress, and surmountable problems of developing markers from plasma.
optimizing protein & antibody therapeutics
January 9-10, 2007
The demand for protein and antibody therapeutics grows by 50% each year, yet manufacturing capacities remain little changed.
Over 250 organizations have approximately 400 therapeutics in development which will reach an estimated $50 billion international market by 2018. Yet the time-consuming and often unpredictable nature of working with protein therapeutics is further hampered by the tremendous cost of developing a product?up to $3 billion.
Therapeutic antibodies have achieved significant successes with over 20 on the market, yet considerable challenges persist.
Seeking to understand the biological properties ? structure and function ? of proteins as therapeutics has led to advancements in screening and characterization technologies.

Improving the stability of proteins continues to be a major goal along with enhanced efficacy and improved delivery systems.

New approaches to engineering antibodies and proteins continue to emerge along with the growing knowledge of the ?interactome.?
Join us as we address the complexities, interrelations, and inner workings of proteins and antibodies in the quest of Optimizing Protein & Antibody Therapeutics.
protein arrays: Proteomics in multiplex
January 9-10, 2007
Protein arrays are poised to become a central proteomics technology allowing for the global observation of biochemical activities on an unprecedented scale. Hundreds or thousands of proteins can be simultaneously screened for protein-protein, protein-nucleic acid, and small molecule interactions. The value of multiplexed protein measurement is being established in applications including: comprehensive proteomic surveys, studies of protein networks and pathways, validation of genomic discoveries, and clinical biomarker development. This technology holds great potential for basic molecular biology research, serum profiling, protein abundance determination, disease biomarker identification, immune and toxicological response profiling, and pharmaceutical target screening. Cambridge Healthtech Institute?s 6th Annual Protein Arrays: Proteomics in Multiplex continues the tradition of providing practical information and results from creative technical solutions supporting a plethora of proteomic applications.
January 11-12, 2007
As protein therapeutics and diagnostics become more and more prevalent in the pharmaceutical and biotechnology repertoire, many of the same problems which have existed in the field continue to plague process development scientists. Issues of host selection, appropriate protein engineering, improving throughput, automation, and production assessment have not been eliminated yet. Many of the tools used for protein expression have been slow to filter downstream to the process development/scale-up portion of the pipeline. Yet, the demand for large amounts of high quality proteins continues to grow. This highly focused meeting will discuss ways to apply the upstream lessons, methods and technologies to large-scale protein production and to discuss methods for solving these ongoing challenges in cost effective and efficient ways.
profiling proteins:
Characterization Insights & Technologies
January 11-12, 2007
The nature and complexity of the ?Interactome? create a perpetual need to better understand protein function and interactions. Whether in the Discovery, Development, Clinical, or Manufacturing phase of a protein-based product, protein characterization is an essential and continuous process.
When characterizing proteins, the question may arise, ?What is the best tool to reach a particular goal?? The goal may be to determine the big picture, or to dig down deeper into a molecule?s properties. The tools needed to achieve the desired results may or may not be the same.
New tools and technologies emerge constantly to help scientists identify what?s in the tube. Your lab may have some of the tools, but perhaps you want to learn about technologies you haven?t worked with, or see how technologies are implemented in different settings.
In the Profiling Proteins: Characterization Insights & Technologies meeting, a full spectrum of technologies will be addressed that are tied into bottom-line applications in order to provide more meaningful insights into the practical uses of today?s characterization tools.
Tel: 781-972-5431
Comments: 0